Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeDisease EducationDisease
EducationDisease EducationDisparitiesEfficacy and SafetyEfficacy and SafetyImmunogenicitySafetyDosing and AdministrationDosing and
AdministrationDosing RecommendationsAdministrationResourcesResourcesOrdering PENBRAYARequest a Representative MaterialsVideos
Prescribing InformationIndicationsTRUMENBARequest a RepLoading
Help close the meningococcal vaccination gap in your community Although MenACWY vaccination rates are high, a retrospective study found that publicly insured patients* who initiate their MenB series are 12% less likely to complete it versus commercially insured patients1†
Scroll left to view table
ReferencesMedicaid patients.This retrospective cohort study used de-identified data from the IBM MarketScan Commercial Chains and Encounters Multi-State Medicaid databases. Individuals with a MenB vaccination were identified during January 2017 through either November 2018 (commercially insured patients) or September 2018 (Medicaid patients). The index date was the date of first MenB vaccination within the study. The baseline period was 6 months earlier; 15 months after served as the follow-up period. The main outcome of the study was the proportion of individuals who completed a MenB vaccine series within 15 months of the first MenB vaccine dose, both overall and separately, for MenB-4C and MenB-FHbp (TRUMENBA).1

PENBRAYA and TRUMENBA are available through the VFC program2

Vaccines for Children (VFC) is a federally funded program that provides vaccines at no additional cost to eligible children younger than 19 years of age.3‡ Please check your state's health department website for more information.

ReferencesChildren qualify for the VFC program if they are younger than 19 years of age and either uninsured, underinsured, Medicaid-eligible or Medicaid-enrolled, or American Indian or Alaska Native.4A retrospective cohort study found that TRUMENBA® (Meningococcal Group B Vaccine) vaccine series completion rates decrease with age among teen patients within 15 months of taking the first dose1§||
Scroll left to view table
ReferencesThe data presented here are completion rates of the study cohort that received only MenB-fHbp [TRUMENBA] during the course of this study.1This retrospective cohort study used de-identified data from the IBM MarketScan Commercial Chains and Encounters Multi-State Medicaid databases. Individuals with a MenB vaccination were identified during January 2017 through either November 2018 (commercially insured patients) or September 2018 (Medicaid patients). The index date was the date of first MenB vaccination within the study. The baseline period was 6 months earlier; 15 months after served as the follow-up period. The main outcome of the study was the proportion of individuals who completed a MenB vaccine series within 15 months of the first MenB vaccine dose, both overall and separately, for MenB-4C and MenB-FHbp (TRUMENBA).1The impact of adopting PENBRAYA® and TRUMENBA® may result in increases of publicly delivered MenB vaccine doses5,6¶#

Learn how a multi-site practice setting was able to increase their MenB vaccination rates with adoption of PENBRAYA and TRUMENBA

Download case study to learn more
LoadingReferencesThe data are derived from the Arkansas population served by Arcare.7In 2024, Arcare experienced a significant increase in MenB vaccination orders compared to 2023, reflecting an upward trend in the adoption of the meningococcal vaccine.6Your recommendation matters
  • A recommendation from a health care provider remains the number one reason parents decide to vaccinate8**
  • With PENBRAYA and TRUMENBA, you can complete the recommended vaccine series in one less dose9††
ReferencesEvidence base from the Centers for Disease Control and Prevention includes studies and national surveys that indicate a positive correlation between a child healthcare provider's strong recommendation and vaccine uptake along with decreased parental concern surrounding vaccination.8One less injection is needed for healthy adolescents at age 16 to complete the meningococcal vaccination schedule compared to separate MenACWY and MenB vaccines.9SCHIP=State Children's Health Insurance Program.References:Packnett ER, Zimmerman NM, Kim G, et al. A real-world claims data analysis of meningococcal serogroup B vaccine series completion and potential missed opportunities in the United States. Pediatr Infect Dis J. 2022;21(4):e158-e165.Centers for Disease Control and Prevention. Vaccines for Children (VFC) Program: CDC vaccine price list. Updated July 1, 2025. Accessed May 28, 2026. https://www.cdc.gov/vaccines-for-children/media/pdfs/2026/03/Pediatric-VFC-Vaccine-Price-List-04-01-26-508.pdfCenters for Disease Control and Prevention. About the Vaccines for Children (VFC) Program. Updated September 30, 2025. Accessed May 28, 2026. https://www.cdc.gov/vaccines-for-children/about/index.htmlCenters for Disease Control and Prevention. Vaccines for Children (VFC) Program eligibility. Updated September 30, 2025. Accessed May 28, 2026. https://www.cdc.gov/vaccines-for-children/hcp/program-eligibility/index.htmlData on file. PENBRAYA and TRUMENBA VFC SCHIP email. Pfizer Inc.Data on file. Arcare case study email. Pfizer Inc.Health Center Program Uniform Data System (UDS) data. Age overview. https://data.hrsa.gov/topics/healthcenters/uds/overview?grant¬Num=H80CS00207Centers for Disease Control and Prevention. Give a strong vaccine recommendation. Updated June 18, 2024. Accessed July 23, 2026. https://www.cdc.gov/iqip/hcp/strategies/strong-vaccine-recommendation.htmlCollins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345·350.PENBRAYA® (Meningococcal Groups A, B, C, W, and Y Vaccine). Prescribing information. Pfizer Inc.; 2026.Disease EducationKicker Simplified dosing

Complete the meningococcal disease vaccine schedule in one less dose.9

 See dosing LoadingKicker Demonstrated immunogenicity

PENBRAYA has demonstrated robust immunogenicity against all 5 vaccine-preventable meningococcal serogroups (MenA, B, C, W, and Y).10

 See immunogenicity Loading

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-PBI-USA-0552
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age 
Important Safety Information
  • Do not administer PENBRAYA or TRUMENBA to individuals with a history of severe allergic reaction (eg, anaphylaxis) to any component of PENBRAYA or TRUMENBA. Appropriate medical treatment used to manage allergic reactions must be available in the event an anaphylactic reaction occurs immediately following administration of PENBRAYA or TRUMENBA
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including PENBRAYA or TRUMENBA. Procedures should be in place to avoid injury from fainting
  • Some individuals with altered immunocompetence may have reduced immune responses to PENBRAYA or TRUMENBA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis groups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENBRAYA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis group B, even if they develop antibodies following vaccination with TRUMENBA
  • Vaccination with PENBRAYA or TRUMENBA may not protect all vaccine recipients
  • Vaccination with PENBRAYA does not substitute for vaccination with a tetanus toxoid–containing vaccine to prevent tetanus
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENBRAYA to individuals with a history of GBS should take into account the expected benefits and potential risks 
  • For PENBRAYA, the most commonly reported (≥15%) solicited adverse reactions after Dose 1 and Dose 2, respectively, were pain at the injection site (89% and 84%), fatigue (52% and 48%), headache (47% and 40%), muscle pain (26% and 23%), injection site redness (26% and 23%), injection site swelling (25% and 24%), joint pain (20% and 18%), and chills (20% and 16%)
  • For TRUMENBA, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)
  • Data are not available on the safety and effectiveness of using TRUMENBA and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • The safety and effectiveness of PENBRAYA or TRUMENBA have not been established in pregnant individuals
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for PENBRAYA and full Prescribing Information for TRUMENBA.Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age